Global Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06251669

Publication Date:

June 27, 2025

Pages:

106

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Placental Stem Cell Therapy for Neurological Disorders market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Placental stem cell therapy for neurological disorders involves the use of stem cells derived from the placenta to treat conditions affecting the nervous system. These cells have the potential to differentiate into various specialized cell types, promoting neural regeneration and repair. This therapeutic approach aims to address conditions like Parkinson"s disease, Alzheimer"s, and spinal cord injuries, offering a promising avenue for regenerative medicine in neurology by harnessing the regenerative capabilities of placental-derived stem cells.
The industry trend for placental stem cell therapy in neurological disorders is marked by ongoing research and clinical trials to explore its efficacy and safety. As advancements in stem cell technology and understanding of neurobiology progress, there"s a growing interest in developing targeted and personalized therapies. Regulatory frameworks are evolving to accommodate these innovative treatments. The trend also involves collaborations between academia, biotech companies, and healthcare institutions to accelerate the translation of research findings into practical and accessible therapeutic solutions, reflecting a positive outlook for the integration of placental stem cell therapy into neurological care.
The 鈥淧lacental Stem Cell Therapy for Neurological Disorders Industry Forecast鈥� looks at past sales and reviews total world Placental Stem Cell Therapy for Neurological Disorders sales in 2024, providing a comprehensive analysis by region and market sector of projected Placental Stem Cell Therapy for Neurological Disorders sales for 2025 through 2031. With Placental Stem Cell Therapy for Neurological Disorders sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Placental Stem Cell Therapy for Neurological Disorders industry.
This Insight Report provides a comprehensive analysis of the global Placental Stem Cell Therapy for Neurological Disorders landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Placental Stem Cell Therapy for Neurological Disorders portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Placental Stem Cell Therapy for Neurological Disorders market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Placental Stem Cell Therapy for Neurological Disorders and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Placental Stem Cell Therapy for Neurological Disorders.
This report presents a comprehensive overview, market shares, and growth opportunities of Placental Stem Cell Therapy for Neurological Disorders market by product type, application, key players and key regions and countries.
Segmentation by Type:
Allogeneic Placental Stem Cell Therapy
Autologous Placental Stem Cell Therapy
Segmentation by Application:
Hospitals and Specialist Clinics
Clinical Research Institute
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Mesoblast
Pleurite Therapeutic
Athersys
Cordlife India
Life Cell
Cryo-Cell
CBR Systems
ReNeuron Group
Cynata
Celularity
Americord Registry
ReeLabs
Mesoblast

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size (2020-2031)
2.1.2 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Placental Stem Cell Therapy for Neurological Disorders by Country/Region (2020, 2024 & 2031)
2.2 Placental Stem Cell Therapy for Neurological Disorders Segment by Type
2.2.1 Allogeneic Placental Stem Cell Therapy
2.2.2 Autologous Placental Stem Cell Therapy
2.3 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Type
2.3.1 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Placental Stem Cell Therapy for Neurological Disorders Segment by Application
2.4.1 Hospitals and Specialist Clinics
2.4.2 Clinical Research Institute
2.5 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Application
2.5.1 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Player
3.1 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Placental Stem Cell Therapy for Neurological Disorders Revenue by Player (2020-2025)
3.1.2 Global Placental Stem Cell Therapy for Neurological Disorders Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Placental Stem Cell Therapy for Neurological Disorders Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Placental Stem Cell Therapy for Neurological Disorders by Region
4.1 Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Region (2020-2025)
4.2 Global Placental Stem Cell Therapy for Neurological Disorders Annual Revenue by Country/Region (2020-2025)
4.3 Americas Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size Growth (2020-2025)
4.4 APAC Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size Growth (2020-2025)
4.5 Europe Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Country (2020-2025)
5.2 Americas Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Type (2020-2025)
5.3 Americas Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Region (2020-2025)
6.2 APAC Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Type (2020-2025)
6.3 APAC Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Country (2020-2025)
7.2 Europe Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Type (2020-2025)
7.3 Europe Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders by Region (2020-2025)
8.2 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Forecast
10.1 Global Placental Stem Cell Therapy for Neurological Disorders Forecast by Region (2026-2031)
10.1.1 Global Placental Stem Cell Therapy for Neurological Disorders Forecast by Region (2026-2031)
10.1.2 Americas Placental Stem Cell Therapy for Neurological Disorders Forecast
10.1.3 APAC Placental Stem Cell Therapy for Neurological Disorders Forecast
10.1.4 Europe Placental Stem Cell Therapy for Neurological Disorders Forecast
10.1.5 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders Forecast
10.2 Americas Placental Stem Cell Therapy for Neurological Disorders Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.2.2 Canada 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.2.3 Mexico 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.2.4 Brazil 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.3 APAC Placental Stem Cell Therapy for Neurological Disorders Forecast by Region (2026-2031)
10.3.1 China Placental Stem Cell Therapy for Neurological Disorders 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.3.3 Korea 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.3.4 Southeast Asia 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.3.5 India 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.3.6 Australia 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.4 Europe Placental Stem Cell Therapy for Neurological Disorders Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.4.2 France 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.4.3 UK 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.4.4 Italy 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.4.5 Russia 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.5 Middle East & Africa Placental Stem Cell Therapy for Neurological Disorders Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.5.2 South Africa 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.5.3 Israel 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.5.4 Turkey 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
10.6 Global Placental Stem Cell Therapy for Neurological Disorders Forecast by Type (2026-2031)
10.7 Global Placental Stem Cell Therapy for Neurological Disorders Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Placental Stem Cell Therapy for Neurological Disorders Forecast
11 Key Players Analysis
11.1 Mesoblast
11.1.1 Mesoblast Company Information
11.1.2 Mesoblast Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.1.3 Mesoblast Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Mesoblast Main Business Overview
11.1.5 Mesoblast Latest Developments
11.2 Pleurite Therapeutic
11.2.1 Pleurite Therapeutic Company Information
11.2.2 Pleurite Therapeutic Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.2.3 Pleurite Therapeutic Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Pleurite Therapeutic Main Business Overview
11.2.5 Pleurite Therapeutic Latest Developments
11.3 Athersys
11.3.1 Athersys Company Information
11.3.2 Athersys Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.3.3 Athersys Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Athersys Main Business Overview
11.3.5 Athersys Latest Developments
11.4 Cordlife India
11.4.1 Cordlife India Company Information
11.4.2 Cordlife India Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.4.3 Cordlife India Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Cordlife India Main Business Overview
11.4.5 Cordlife India Latest Developments
11.5 Life Cell
11.5.1 Life Cell Company Information
11.5.2 Life Cell Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.5.3 Life Cell Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Life Cell Main Business Overview
11.5.5 Life Cell Latest Developments
11.6 Cryo-Cell
11.6.1 Cryo-Cell Company Information
11.6.2 Cryo-Cell Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.6.3 Cryo-Cell Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Cryo-Cell Main Business Overview
11.6.5 Cryo-Cell Latest Developments
11.7 CBR Systems
11.7.1 CBR Systems Company Information
11.7.2 CBR Systems Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.7.3 CBR Systems Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 CBR Systems Main Business Overview
11.7.5 CBR Systems Latest Developments
11.8 ReNeuron Group
11.8.1 ReNeuron Group Company Information
11.8.2 ReNeuron Group Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.8.3 ReNeuron Group Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 ReNeuron Group Main Business Overview
11.8.5 ReNeuron Group Latest Developments
11.9 Cynata
11.9.1 Cynata Company Information
11.9.2 Cynata Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.9.3 Cynata Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Cynata Main Business Overview
11.9.5 Cynata Latest Developments
11.10 Celularity
11.10.1 Celularity Company Information
11.10.2 Celularity Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.10.3 Celularity Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Celularity Main Business Overview
11.10.5 Celularity Latest Developments
11.11 Americord Registry
11.11.1 Americord Registry Company Information
11.11.2 Americord Registry Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.11.3 Americord Registry Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Americord Registry Main Business Overview
11.11.5 Americord Registry Latest Developments
11.12 ReeLabs
11.12.1 ReeLabs Company Information
11.12.2 ReeLabs Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.12.3 ReeLabs Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 ReeLabs Main Business Overview
11.12.5 ReeLabs Latest Developments
11.13 Mesoblast
11.13.1 Mesoblast Company Information
11.13.2 Mesoblast Placental Stem Cell Therapy for Neurological Disorders Product Offered
11.13.3 Mesoblast Placental Stem Cell Therapy for Neurological Disorders Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Mesoblast Main Business Overview
11.13.5 Mesoblast Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.